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lent alternative source of MSCs. The aim of this study was to
compare different enrichment methods of obtaining MSCs from
CB, to generate sufﬁcient numbers of MSCs for transplantation.
The plastic adhesion method (PAM) and the depleting method
RosetteSep (DMR) on fresh CB units were compared. Both cell
fractions were grown in Mesencult complete medium. Their pro-
liferative capacity and their phenotype during culture were tested.
The MSC phenotype was evaluated by expression of CD105,
glycophorin A, CD29, CD44, CD45, CD31, CD34, CD64,
CD62L, CD106, CD117, CD133, CD90, HLA-class I, HLA-DR,
CD1a, CD3, CD51, and CD58. Sufﬁcient numbers of cells (56.6
9.2%) were recovered after the PAM and only a few cells (5.3 
2.6%) were isolated from the whole CB using the DMR. After the
second passage, the PAM allowed 155.5  62.9% of MSCs to be
obtained, whereas 108.3  0.99% of MSCs were obtained by the
DMR. For both methods, 3 passages were needed to obtain com-
parable homogeneity, corresponding to an average of 45 days. The
CB-derived MSCs were positive for the matrix receptors CD44,
CD58, and CD105; the integrins CD29 and CD51; and the mark-
ers CD90 and HLA-class I. They were negative for the matrix
receptors CD31 and CD62L, as well as the hematopoietic markers
CD45, CD34, CD133, CD64, CD117, CD1a, CD3, and HLA-
DR. In conclusion, both methods may represent an easy way of
obtaining MSCs from CB with the aim of potential use in CB
transplantation, because MSCs facilitate and promote the overall
engraftment level of multidonor CB grafts.
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WEIGHT LOSS IN PEDIATRIC PATIENTS WITH CHRONIC GRAFT-VER-
SUS-HOST DISEASE (CGVHD)
Browning, B., Thormann, K., Tse, W., Duerst, R., Kletzel, M.,
Jacobsohn, D.A. Children’s Memorial Hospital, Northwestern Univer-
sity, Chicago, IL.
Weight loss and malnutrition are major problems in patients with
cGVHD. In adults, a low body mass index (BMI) is a predictor for
mortality; however, weight loss and BMI have not been studied in
pediatric patients with cGVHD. A retrospective study of 18 pa-
tients at Children’s Memorial Hosptial with extensive cGVHD
based on the revised Seattle Classiﬁcation was completed. Median
age at SCT was 11.5 years (range, 1–22 years); age at cGVHD
diagnosis was 12 years (range, 1–23 years). Median duration of
immunsuppressive therapy was 15.5 months (range, 3–51 months).
Maximum height, weight, and BMI change were calculated from
date of SCT through the duration of cGVHD treatment. Patients
were also graphed on standard growth charts. Patients were strat-
iﬁed into groups based on the number of organ systems involved.
Patients with multiorgan involvement had a mean maximal BMI
decrease of &minus9%, and 50% of these patients had a decrease
of 1–4 quintiles on standard weight-for-age growth charts and
remain at less than the 10th percentile in expected weight for age.
This change in BMI not only indicates a signiﬁcant decrease in
weight but also often a plateau in stature. The resolution of oral
and GI symptoms did not appear to reverse this weight loss trend,
which indicates a structural alteration in the GI tract or an in-
creased metabolic rate. All of the patients with multiorgan involve-
ment required salvage therapy beyond steroids and CSA, and 3 of
them died due to complications of cGVHD. All patients with
single organ involvement have resolved their cGVHD with stan-
dard therapy. Weight loss and malnutrition are clinically signiﬁ-
cant issues in pediatric patients with multisystem cGVHD. Weight
loss is likely another systemic manifestation of the disease and may
contribute to increased mortality in this group. Studies measuring
resting energy expenditure and intestinal permeability are under-
way to further understand the nature of weight loss in this popu-
lation.
>1 Organ Involved 1 Organ Involved P
Number of
patients
11 7
Age at HSCT 10.2 years
(5.7–14.5)
14.5 years
(11.8–17.3)
0.1
Age at cGVHD
diagnosis
10.5 years
(5.8–15)
14.7 years
(12.1–17.3)
0.14
Length of therapy 19.5 months
(10.9–28.1)
14.2 months
(12.2–16.3)
0.3
Sites of
involvement
Skin/MS 11/11 2/7 0.002
Liver 3/11 5/7 0.08
Oral 7/11 0/7 0.01
GI 2/11 0/7 0.3
Lung 1/11 0/7 0.6
Max BMI change 9% (17.6%–1.2%) 10.2% (2%–20.8%) 0.003
Max weight
change
4% (13%–5%) 14.8% (2.2%–27.4%) 0.01
Median # quintiles
dropped
1.5 (0-4) 0 (0-0) —
Weight under
25%ile
6/10 0/7 0.01
Weight under
10%ile
5/10 0/7 0.04
Deaths 3/11 0/7 0.2
Continuous variables expressed as mean with 95% CI unless where
noted. Frequencies are compared using Fisher’s exact test.
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EVALUATION OF ORAL MUCOSITIS USING A SELF-REPORTED QUES-
TIONNAIRE IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES UN-
DERGOING HIGH-DOSE CHEMORADIOTHERAPY FOLLOWED BY PE-
RIPHERAL BLOOD PROGENITOR CELL TRANSPLANTATION
Stiff, P.J.1, Bensinger, W.I.2, Emmanouilides, C.3, Gentile, T.4,
Okano, G.5, Lu, J.5, Erder, M.H.6, Spielberger, R.7 1Loyola University,
Maywood, IL; 2Fred Hutchinson Cancer Research Center, Seattle, WA;
3UCLA Medical Center, Los Angeles, CA; 4SUNY Upstate Medical
University, Syracuse, NY; 5Amgen, Inc., Thousand Oaks, CA; 6Forest
Laboratories, Inc., Jersey City, NJ; 7City of Hope National Medical
Center, Duarte, CA.
Background: Oral mucositis (OM) is a frequent complication
experienced by patients with hematologic malignancies (HMs)
undergoing high-dose chemoradiotherapy (CRT) followed by pe-
ripheral blood progenitor cell transplantation (PBPCT). Patients
rate OM as the most debilitating side effect of hematologic trans-
plantation. In clinical trials, physicians assess the severity of OM
using 1 or more established clinical scales such as the WHO,
WCCNR, or RTOG. In a pivotal phase 3 randomized, placebo-
controlled, double-blind clinical trial of palifermin (a rHuKGF
molecule) in HM patients, patients assessed their OM severity and
impact on daily functions through a self-reported OM daily ques-
tionnaire (OMDQ). We compared these patient self-reporting
results with established clinical OM scales (WHO, WCCNR, and
RTOG) and report the ﬁndings here. Methods: Over a period of
40 days, patient reported mouth and throat soreness (MTS) and its
impact on swallowing, eating, drinking, talking, and sleeping
(MTS-AL) were assessed daily using the OMDQ in 212 patients
(placebo, n  106; palifermin, n  106). The mean daily compli-
ance rate for completing the self-reporting questionnaires over the
entire study period was 84% in the placebo group and 89% in the
palifermin group. The Pearson correlation coefﬁcients between
MTS/MTS-AL scores and clinical OM scales at days 7 and 14
posttransplantation and between the change in scores in MTS/
MTS-AL and clinical OM scales between days 7 and 14 posttrans-
plantation were calculated. The daily OM severity grades, as mea-
sured by OMDQ, WHO, WCCNR, and RTOG, were graphed
for comparison. Results: Patients were able to detect the increases
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and decreases in severity of OM earlier (from 1 to 3 days) using
the MTS than their physicians who were using the 3 OM
clinical scales. The self-reported OM pain score was worst at
day 5 for MTS, compared to day 7 for the 3 clinical scales.
Correlation of the MTS/MTS-AL scores at days 7 and 14 was
strongest with the WHO scale (0.25–0.55). MTS/MTS-AL
correlation was next strongest with the WCCNR scale (0.27–
0.49), followed by the RTOG scale (0.29–0.44). Similarly, the
changes in mean scores were signiﬁcantly correlated between
MTS (0.29) or 4 of 5 MTS-AL (0.28–0.33) and the WHO scale.
Conclusion: The patient self-reported severity and impact of
OM measure correlated well with the clinical measures, espe-
cially with the WHO scale. In addition, the patient self-reported
measure can consistently detect changes (both increases and
decreases) in the severity of OM earlier than can any of the OM
clinical measures.
Table 1. Correlation of MTS Questions With WHO Clinical OM
Scale
MTS Questions
Mean Score Correlation Coefficient (r)
Day 7 Day 14
Change in Mean
Score (Day 7
to Day 14)
MTS (mouth and throat
soreness) 0.46 (n  174) 0.49 (n  113) 0.29 (n  100)
MTS-S (swallowing) 0.50 (n  174) 0.38 (n  113) 0.29 (n  100)
MTS-D (drinking) 0.54 (n  173) 0.43 (n  113) 0.30 (n  99)
MTS-E (eating) 0.55 (n  173) 0.41 (n  113) 0.33 (n  99)
MTS-T (talking) 0.45 (n  172) 0.35 (n  113) 0.28 (n  99)
MTS-SL (sleeping) 0.30 (n  170) 0.25 (n  113) 0.08 (n  97)
NOTE: P-values are Day 7: p 0.001; Day 14: p 0.008; Change
in mean score: p 0.005 (for MTS, MTS-S, MTS-D, MTS-E,
MTS-T); Change in mean score: p  0.428 (for MTS-SL
only).
214
LONG-TERM QUALITY OF LIFE IS NOT AFFECTED BY AGE IN AML/MDS
PATIENTS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANS-
PLANTATION
Shahjahan, M., Alamo, J., Giralt, S., Detry, M., Munsell, M.,
Estey, E., Champlin, R., de Lima, M. University of Texas M.D.
Anderson Cancer Center, Houston, TX.
Objective: Allogeneic hematopoietic stem cell transplantation
(alloHSCT) can have signiﬁcant impact on patients’ quality of
life (QOL) in the long term. We seek to describe QOL of
long-term survivors with AML/MDS and compare QOL as a
function of age at transplant. Methods: Between January 1976
and September 2001, 544 adult AML/MDS patients received
alloHSCT at our institution. Long-term survivorship was de-
ﬁned as survival in remission beyond 2 years post-HSCT be-
cause failure rate stabilized in the third year. A total of 129
(24%) patients in remission for at least 2 years were eligible.
QOL was assessed with Functional Assessment of Cancer Ther-
apy-Bone Marrow Transplant (FACT-BMT) questionnaire
measuring physical, functional, social/family, and emotional
well-being (PWB, FWB, SFWB, EWB), including doctor–pa-
tient relationship (RWD). An additional concern (AC) subscale
also asked questions related to bone marrow transplantation.
Response rate was 68%. A higher score on the FACT-BMT
reﬂected a higher QOL. Demographic and clinical data were
collected from medical records and clinical database. Results:
The median patient age at transplantation was 38.44 years
(range, 18.54–68.08 years). The study group comprised 47
males and 35 females, 70 with a diagnosis of AML and 12 with
a diagnosis of MDS. Conditioning was with reduced intensity
regimen (RI) in 29 cases and myeloablative regimen (MA) in 53
cases. The stem cell source was the bone marrow in 52 cases and
peripheral blood in 30 cases. Disease status at HSCT was
complete remission in 40 cases, relapsed in 37 cases, and un-
treated disease in 5 cases. Median follow-up time was 4.53 years
(range, 2.0–21.1 years). There were no signiﬁcant differences
between the older and younger patients (above and below the
median age at transplant) on the PWB, SFWB, EWB, FWB,
and RWD subscales. On the AC subscale, older patients had
higher QOL scores than younger patients (mean score, 37.97 vs
33.25, respectively; P  .005). There were no signiﬁcant differ-
ences in QOL scores between patients receiving RI and MA
regimen in all but the AC subscale where RI group had a higher
score (39.00 vs 33.34, respectively; P  .001). Acute graft-
versus-host disease (GVHD) did not impact long-term QOL,
but lack of chronic GVHD was associated with better QOL
score in the PWB, EWB, FWB, and AC subscales (PWB, 25.04
vs 20.62, P  .005; EWB, 21.77 vs 18.98, P  .003; FWB, 22.91
vs 18.00, P  .008; AC, 40.00 vs 34.28, P  .002). Conclusion:
Older age at transplantation did not affect the QOL in long-
term survivors with AML/MDS after alloHSCT.
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RISK FACTORS FOR CHRONIC KIDNEY DISEASE (CKD) AFTER HEMA-
TOPOIETIC CELL TRANSPLANTATION (HCT)
Hingorani, S.R.1, Guthrie, K.2, Schoch, G.2, McDonald, G.D.1,2 1Uni-
versity of Washington, Seattle, WA; 2Fred Hutchinson Cancer Research
Center, Seattle, WA.
CKD has been reported in 20% of adult and 62% of children in
the years following HCT, usually becoming apparent 6–12 months
after transplant. Mortality rates are higher in patients with CKD in
this setting than in transplantation recipients who retain normal
renal function. Although there are numerous case series describing
CKD in the setting of HCT, they involve relatively small cohorts
of patients. We examined the frequency of CKD and risk factors
for its development in a large cohort of patients transplanted over
a 10-year time span.Methods:We reviewed data from consecutive
patients who received their ﬁrst transplantation between 1991 and
2002 and who had at least 2 serum creatinine values between days
100 and 540 posttransplantation, and at least 1 measurement
within 3 months of day 365 or death, whichever came ﬁrst. CKD
was deﬁned as a serum creatinine level 1.5 mg/dL in men, 1.3
mg/dL in women and  0.9 mg/dL in children at 2 or more times
during day 100–540 posttransplantation. Putative risk factors an-
alyzed included demographic characteristics, type of transplanta-
tion, conditioning regimen (including irradiation) and comorbidi-
ties such as acute graft-versus-host disease (GVHD) and acute
renal failure (ARF), deﬁned as doubling of baseline creatinine
before day 60. Using univariable and multivariable Cox regression
models, hazard ratios for associations of risk factors with CKD
were estimated. Results: A total of 1593 patients, with 279 cases of
CKD (17.5%), made up the study sample. The 279 cases of CKD
occurred at a median of 108 days posttransplantation, with a range
of 100–517 days. In a multivariable Cox regression model, adjusted
for age, sex, diagnosis, donor and transplantation type, total body
irradiation (TBI), cyclosporine prophylaxis, and acute and chronic
GVHD, ARF was a signiﬁcant predictor of CKD (hazard rate 
2.0, 95% comfodence interval  1.6–2.6). Age, mean total serum
bilirubin through day 100, grades 3 and 4 acute GVHD, and
chronic GVHD were also signiﬁcantly associated with CKD after
adjusting for all other factors. TBI and donor and transplantation
type were not associated with an increased risk of CKD in the
multivariable model. Conclusions: The prevalence of CKD to 1
year posttransplantation is 17.5%. ARF, jaundice, severe acute
GVHD, and chronic GVHD are associated with an increased risk
of CKD. Those patients with ARF who survive beyond day 100
should be considered for intervention trials as they are at highest
risk.
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